Remove 2007 Remove Pharmaceuticals Remove Pharmacy
article thumbnail

Dr. Lolettima O. Johnson Celebrated for Dedication to the Field of Medicine

The Pharma Data

With years of pharmaceutical expertise to her credit, Dr. Johnson first garnered inspiration for her professional future during her formative years. Doctor Johnson has had an inspiring career that encompasses several aspects of the pharmacy industry. About Marquis Who’s Who® Since 1899, when A.

article thumbnail

Gilead agrees to pay $97 million to settle Medicare kickbacks case

The Pharma Data

This allowed Gilead to boost their revenue from June 2007 to December 2010, which violated the federal False Claims Act. This legislation specifically outlaws pharmaceutical companies from offering anything of value to incentivise Medicare patients to buy their drugs. . Conor Kavanagh. Source link.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Analysis Life Sciences Thank You After 13-year review, FDA finalizes ‘clear, conspicuous and neutral’ drug advertising rule

Agency IQ

The requirement related to the presentation of side effects and contraindications was amended in 2007, with the passage of the Food and Drug Administration Amendments Act (FDAAA). Pharmaceutical companies asked the FDA to use this opportunity to rethink how much risk information is appropriate for an ad.

FDA 40
article thumbnail

Final Ruling on Medicare Most-Favored-Nation Drug Pricing Set for Federal Register Publication

The Pharma Data

A study of 600 brand-name drugs, conducted at the University of Pittsburgh Center for Pharmaceutical Policy and Prescribing (CP3) earlier this year, found that list prices increased 159% between 2007 and 2018. in 2019, according to a report in the American Journal of Health-System Pharmacy. billion in 2019 (up 1.5%

Drugs 52
article thumbnail

NPP, DCC, And FDA-Regulated Medical Products

Drug & Device Law

In that Fourth Circuit case we mentioned above , the court looked to Healy (which knocked out a Connecticut wholesale beer pricing law) and Pharmaceutical Research & Manufacturers of America v. One of those laws, FDAAA in 2007, established the REMS system, which reflects the importance of national uniformity in the delivery of healthcare.

article thumbnail

The FDA and Feasible Alternative Designs

Drug & Device Law

The court in Wolfe refused to impose a negligence duty on the defendant pharmaceutical company to develop and obtain FDA approval of the plaintiff’s non-FDA-approved alternative. In at least the short term, a popular pain reliever would have to be removed from pharmacies. This would run counter to. . . 2d at 571.

FDA 59
article thumbnail

Dobbs Would Likely Have Significant Impacts On Drug And Device Companies

Drug & Device Law

Even with some attempt to “stay in our lane,” we can see significant impacts on the legal framework in which a number of medical product manufacturers, to say nothing of distributors, pharmacies, and healthcare providers, operate. 124 (2007), which would also be knocked out by Dobbs if it sticks. Both of these cases applied the U.S.